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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies and
tends to be relatively resistant to conventional therapies. Activated Ras oncogene mutations are found in up to
90% of PDAC, leading to activation of the Ras/Raf/MEK/ERK signaling pathway. Sorafenib is a multikinase inhibitor of
the Ras/Raf/MEK/ERK pathway and of tumor angiogenesis. Endothelial monocyte activating polypeptide II (EMAP)
enhances gemcitabine effects in PDAC. Antitumor activity of sorafenib was evaluated in combination with
gemcitabine (Gem) and the antiangiogenic agent EMAP in experimental PDAC.
Methods: Cell proliferation and protein expression were analyzed by WST-1 assay and Western blotting. Animal
survival studies were performed in murine PDAC xenografts.
Results: Sorafenib decreased phospho-MEK, phospho-ERK1/2, phospho-p70S6K and phospho-4EBP-1 expression in
PDAC cells. Sorafenib inhibited in vitro proliferation of all four PDAC cell lines tested. Additive effects on cell
proliferation inhibition were observed in the gemcitabine-sorafenib combination in PDAC cells, and in
combinations of sorafenib or EMAP with gemcitabine in endothelial (HUVEC) and fibroblast (WI-38) cells. Sorafenib,
alone or in combination with gemcitabine and EMAP, induced apoptosis in HUVECs and WI-38 cells as observed via
increased expression of cleaved poly (ADP-ribose) polymerase-1 (PARP-1) and caspase-3 proteins. Compared to
controls (median survival: 22 days), animal survival increased after Gem therapy (29 days) but not in sorafenib
(23 days) or EMAP therapy alone (25 days). Further increases in survival occurred in combination therapy groups
Gem+sorafenib (30 days, p=0.004), Gem+EMAP (33 days, p=0.002), and Gem+sorafenib+EMAP (36 days, p=0.004),
but not after the sorafenib+EMAP combination (24 days).
Conclusions: These findings demonstrate that the addition of a polymechanistic antiangiogenic agent such as
EMAP can enhance the combination treatment effects of sorafenib and cytotoxic PDAC therapy.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains a
deadly human cancer with very poor prognosis and a
5-year survival of less than 5% [1]. This is primarily related
to its late clinical presentation, early and aggressive
local or metastatic progression and high resistance to
conventional chemotherapy and radiation treatments.
Gemcitabine (Gem), a cytotoxic nucleoside analog, is
the most widely used single agent chemotherapeutic
treatment for locally advanced and metastatic PDAC
[2]. The efficacy of gemcitabine remains modest with a
median survival of approximately 6 months and one-
year survival of less than 20% [2-4]. Currently several
clinical studies are underway to explore combination
treatment benefits of gemcitabine with other cytotoxic,
antiangiogenic or targeted agents for novel and more
effective therapeutic strategies for PDAC. In addition,
FOLFIRINOX is a combination cytotoxic regimen that
has shown a somewhat greater efficacy but also greater
toxicity potential compared to gemcitabine [5].
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The K-ras oncogene is mutated in up to 90% of
PDAC [6-8], leading to constitutive activation of the
Ras/Raf/MEK/ERK signal transduction pathway and
suggesting that this pathway could represent an im-
portant target for PDAC therapy. Sorafenib (So,
Nexavar, BAY 43-9006) is a novel, potent, orally avail-
able multikinase inhibitor targeting Raf serine/threo-
nine kinases as well as different receptor tyrosine
kinases including vascular endothelial growth factor
receptor (VEGFR), platelet derived growth factor
receptor (PDGFR), c-Kit, FLT-3 and RET [9,10]. In
preclinical studies sorafenib has shown significant
antitumor responses in several tumor types including
renal cell carcinoma, pancreatic cancer, colon cancer,
breast cancer and melanoma based in part on its in-
hibitory effect on the Ras/Raf/MEK/ERK and angio-
genesis pathways [9-11]. Sorafenib is approved for the
clinical treatment of hepatocellular carcinoma and
renal cell carcinoma [12]. A phase I trial of sorafenib
plus gemcitabine in advanced PDAC showed that this
combination was well tolerated and that 57% patients
experienced stable disease [13]. More recently, a phase II
trial of sorafenib plus gemcitabine showed no significant
clinical activity in advanced PDAC [14]. These results sup-
port an evaluation of the addition of other antitumor
agents to sorafenib plus gemcitabine for targeting multiple
pathways that partake in PDAC progression.
Activated angiogenesis mechanisms are essential for the
progression of primary and metastatic solid tumors includ-
ing PDAC. Antiangiogenic agents including bevacizumab,
an antibody against vascular endothelial growth factor
(VEGF) [15,16], the matrix metalloproteinase inhibitor
marimastat [17], the cyclooxygenase-2 inhibitor celecoxib
[18] and various other TKIs [19] have been tested clin-
ically in PDAC with limited survival benefit [20]. Endo-
thelial monocyte activating polypeptide II (EMAP, E) is
a proinflammatory cytokine with antiangiogenic and
antiendothelial activities. Although EMAP has no effect
on in vitro AsPC-1 PDAC cell line proliferation or
apoptosis [21,22], it has potent effects on endothelial
cells (ECs) such as inhibition of proliferation, migration
and vascularization as well as induction of apoptosis
[23,24]. EMAP has been shown to suppress primary
and metastatic tumor growth [23,25,26] that could be
related to its ability to bind VEGF receptors and α5β1
integrin, leading to interference in fibronectin- and
VEGF signaling [27,28]. EMAP has recently been
shown to improve gemcitabine and docetaxel response
in experimental PDAC [21,29,30]. In the present study,
we tested the hypothesis that combination treatment of
EMAP with sorafenib and gemcitabine can enhance
antitumor effects by blocking multiple critical pathways
leading to progression of PDAC, to define an option for
future PDAC clinical applications.
Materials and methods
Materials
Gemcitabine was purchased from Eli Lilly (Indianapolis,
IN). Sorafenib was purchased from LC Laboratories, Inc.
(Woburn, MA). Recombinant human EMAP was prepared
as previously described [31], and the cell proliferation re-
agent WST-1 was purchased from Roche Diagnostic
Corporation (Indianapolis, IN).
Cell culture
The human pancreatic cancer cell line AsPC-1, human
umbilical vein endothelial cells (HUVECs) and human
fibroblast cell line WI-38 were all purchased from the
American Type Culture Collection (ATCC, Rockville, MD).
AsPC-1 and WI-38 cells were grown in RPMI 1640
medium and DMEM, respectively (Sigma Chemical Co. St.
Louis, MO) supplemented with 10% fetal bovine serum
(FBS). HUVECs were grown in EndoGRO-LS medium
containing endothelial cell growth supplements (Millipore
Corp., Billerica, MA).
Cell viability assay
In vitro cell viability was evaluated by using WST-1 re-
agent as per the manufacturer’s instructions. Briefly,
four thousand cells were plated in a 96-well plate and
after 16 hours the medium was replaced with low
serum medium. Cells were treated with gemcitabine,
sorafenib and EMAP. The range of concentrations
used for gemcitabine, sorafenib and EMAP were from
100 nM to 10 μM. After a 72-hour incubation, WST-1
reagent (10 μl) was added in each well and after 2
hours absorbance was measured at 450 nm using a
microplate reader.
Western blot analysis
Cell monolayers were treated with gemcitabine (10 μM),
sorafenib (10 μM) or EMAP (10 μM) and incubated for
16 hours. Total cell lysates were prepared, and equal
amounts of protein were separated by SDS-PAGE and
transferred to PVDF membranes (Bio-Rad, Hercules,
CA). The membranes were blocked for 1 hour in
blocking solution (5% milk in TBS-T [Tris-buffered
saline containing Tween-20]) and incubated overnight at
4°C with the following antibodies: phospho-MEK
(Ser221), total-MEK, phospho-ERK1/2 (Thr202/Tyr204),
total-ERK1/2, phospho-p70 S6 kinase (Thr389), total-p70
S6 kinase, phospho-4E-BP1 (Thr37/46), Total-4E-BP1,
cleaved poly (ADP-ribose) polymerase-1 (PARP-1), cleaved
caspase-3 (all from Cell Signaling Technology, Beverly,
MA) or α-tubulin (Sigma). After primary antibody incuba-
tion, the membranes were incubated for 1 hour with corre-
sponding HRP-conjugated secondary antibodies (Pierce
Biotechnologies, Santa Cruz, CA). Protein bands were
detected using ECL reagent (Perkin Elmer Life Sciences,
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Boston, MA) on autoradiographic film and quantitated by
densitometry.
Animal survival analysis
All animal procedures were performed according to
the guidelines and approved protocols of the University
of Texas Southwestern Medical Center (Dallas, TX)
Institutional Animal Care and Use Committee (Animal
Protocol Number 2008-0348). Animal survival studies
were performed using 6- to 8-week-old female SCID
mice, as previously described [32]. Briefly, mice were
intraperitoneally injected with AsPC-1 cells (0.75x106),
after two weeks mice were randomly grouped (n=6 to 8
per group) and treated intraperitoneally with PBS (con-
trol), gemcitabine (100 mg/kg, twice per week), sorafenib
(30 mg/kg, 5 times per week) or EMAP (80 μg/kg, 5 times
per week) for next two weeks. Animals were euthanized
when appeared moribund according to predefined criteria
including rapid body weight gain or loss (>15%), tumor
size, lethargy, inability to remain upright and lack of
strength. Animal survival was evaluated from the start of
therapy until death. Two mice (one each from Gem+E
and Gem+So+E groups) were removed from the study
during the treatment period due to early development of
severe toxicity.
Statistical analysis
In vitro cell proliferation assay and Western blot densi-
tometric analysis results are expressed as mean ± stand-
ard deviation (SD). Statistical significance was analyzed
by the two-tailed Student’s t-test using GraphPad Prism
4 Software (GraphPad Software, San Diego, CA).
Statistical differences in animal survival studies were
analyzed with StatView for Macintosh version 5.0.1
(SAS, Carey, NC) by nonparametric survival statistics
and logrank testing. P values of <0.05 were considered
to represent statistically significant group differences.
Results
Effect of sorafenib on Ras/Raf/MEK/ERK signaling
Evaluation of the sorafenib effect on the Ras/Raf/MEK/
ERK signaling pathway in human PDAC cell lines re-
vealed that 4-hour sorafenib treatment (10 μM) caused a
significant decrease in the expression of phospho-MEK
(Ser221), phospho-ERK1/2 (Thr202/Tyr204) and the
downstream signaling proteins phospho-p70 S6 kinase
(Thr389) and phospho-4E-BP1 (Thr37/46) in AsPC-1,
Panc-1 and MIA PaCa-2 cells (Figure 1). In BxPC-3
cells, sorafenib caused significant decrease in phospho-
MEK and phospho-ERK but no significant change in
downstream signaling proteins phospho-p70S6K and
phospho-4E-BP1 (Figure 1). In the present study, we
evaluated the effect of sorafenib on phospho-p-70S6K
and phospho-4E-BP1 as these proteins have recently
been shown to be downstream effectors of both AKT/
mTOR and MEK/ERK signaling cascades [33].
Effect of gemcitabine and sorafenib on PDAC cell
proliferation
In vitro cell proliferation analysis of PDAC cells showed
that gemcitabine and sorafenib both inhibited PDAC cell
line proliferation but had differential inhibitory effects.
At 10 μM concentration of gemcitabine, percent inhib-
ition in cell proliferation was 36, 86, 49 and 70 in AsPC-1,
Figure 1 Sorafenib inhibits the Raf/MEK/ERK signaling pathway. Human PDAC cells (AsPC-1, BxPC-3, Panc-1, MIA PaCa-2) were treated with
sorafenib (So) (10 μM) for 4 hours. Total cell extracts were analyzed by immunoblotting for p-MEK (Ser221), total MEK, p-ERK1/2 (Thr202/Tyr204),
total ERK, p-p70 S6K (Thr389), total p70 S6K, p-4E-BP1 and total 4E-BP1 proteins. Data are representative of two independent experiments with
similar results.
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BxPC-3, Panc-1 and MIA PaCa-2 cells, respectively. At
10 μM concentration of sorafenib, percent inhibition
in cell proliferation was 85, 99, 89 and 93 in AsPC-1,
BxPC-3, Panc-1 and MIA PaCa-2. The combination of
gemcitabine and sorafenib had stronger inhibitory effects
on the proliferation of all four PDAC cells at almost all
concentrations tested (Figure 2). A relatively greater
inhibitory effect of combination treatment on PDAC
proliferation was more obvious at lower concentrations.
Percent inhibition in cell proliferation after 100 nM
gemcitabine was 11, 54, 17 and 39, after 100 nM
sorafenib 1, 15, 1 and 17, and after combination of
these two agents 21, 65, 31 and 59 in AsPC-1, BxPC-3,
Panc-1 and MIA PaCa-2, respectively (Figure 2).
Effect of gemcitabine, sorafenib and EMAP on EC and
fibroblast proliferation
Targeting endothelial cells and fibroblasts for solid tumor
treatment has been shown to be potentially quite effective
[34,35]. In our study, analysis of in vitro HUVEC and WI-
38 cell proliferation in growth factor containing medium
revealed that single agent gemcitabine, sorafenib and
EMAP induced significant dose-dependent inhibitory
effects. Importantly, combination of these agents had
some additive effects on inhibition of cell proliferation of
both cell lines. At an intermediate concentration of
gemcitabine (1 μM), sorafenib (1 μM) and EMAP (1 μM),
the percent inhibition in HUVEC proliferation was 63, 69,
53, 79, 82, 72 and 79 in the Gem, So, EMAP, Gem+So,
Gem+EMAP, So+EMAP and Gem+So+EMAP groups,
respectively. In fibroblast WI-38 cells at an intermediate
concentration of gemcitabine (500 nM), sorafenib (500
nM) and EMAP (500 nM) the percent inhibition in WI-38
proliferation was 73, 66, 49, 80, 82, 77 and 83 in the
Gem, So, EMAP, Gem+So, Gem+EMAP, So+EMAP
and Gem+So+EMAP groups, respectively (Figure 3).
Effect of gemcitabine, sorafenib and EMAP on apoptosis
markers
Western blot analysis to evaluate if inhibition in cell pro-
liferation was due to the induction in apoptosis revealed
that sorafenib treatment either alone or in combination
with gemcitabine and EMAP induced apoptosis as ob-
served via PARP-1 cleavage and caspase-3 cleavage in
HUVECs and WI-38 cells (Figure 4). Sorafenib-induced
expression of cleaved PARP-1 and cleaved caspase-3 was
similar in HUVECs and WI-38 cells. Gemcitabine
caused a significant increase in PARP-1 or caspase-3
cleavage in WI-38 fibroblast cells but no detectable
change in HUVECs (Figure 4). EMAP treatment caused
a small change in these apoptosis marker protein in
HUVECs but not in WI-38 cells. In a parallel setting
with AsPC-1 PDAC cells, no detectable change in apop-
tosis marker proteins was observed after gemcitabine,
sorafenib or EMAP treatment (data not shown).
Effect of gemcitabine, sorafenib and EMAP on animal
survival
In vivo animal survival studies in SCID-NOD mice resulted
in a median survival (m.s.) of 22 days in the control group
Figure 2 Gemcitabine (Gem) and sorafenib (So) inhibit in vitro cell proliferation of PDAC cells. AsPC-1, BxPC-3, Panc-1 and MIA PaCa-2
cells were plated on 96-well plates and treated with gemcitabine and sorafenib. After 72 hours, 10 μl WST-1 reagent was added in each well and
incubated for 2 additional hours. The absorbance at 450 nm was measured using a microplate reader. The resulting number of viable cells was
calculated by measuring absorbance of color produced in each well. Data are the mean ± SD of triplicate determinations.
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Figure 3 Gemcitabine (Gem), sorafenib (So) and EMAP (E) inhibit in vitro cell proliferation of EC (HUVECs) and fibroblast cells (WI-38).
Cells were plated on 96-well plate and treated with gemcitabine, sorafenib and EMAP. After 72 hours incubation, WST-1 reagent was added in
each well and number of viable cells was calculated by measuring absorbance of color produced in each well. Data are representative of mean
values ± SD of triplicate determinants. Symbols +, * and • represent p values of less than 0.05, 0.005 and 0.0005 compared to controls.
Figure 4 Effects of gemcitabine (G), sorafenib (So) and EMAP (E) treatment on cleavage of PARP-1 and caspase-3 proteins. A sub-
confluent cell monolayer was treated with gemcitabine (10 μM), sorafenib (10 μM) and EMAP (10 μM). After 16 hours of incubation, total cell
lysate was prepared and analyzed by immunoblotting for cleaved PARP-1, cleaved caspase-3 and α-tubulin (loading control) proteins. The
intensity of bands was quantitated by densitometry and is represented as the bar graph for cleaved PARP-1 (open bar) and cleaved caspase-3
(closed bar) after normalizing against α-tubulin expression. Data are representative of two independent experiments with similar results.
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without treatment. Median animal survival was increased
significantly after Gem (29 days, p=0.009 vs. control) but
not after sorafenib (23 days, p=0.67 vs. control) or EMAP
(25 days, p=0.11) monotherapy (Figure 5). Further improve-
ment in animal survival was encountered in the combin-
ation therapy groups Gem+So (m.s. 30 days, p=0.004 vs.
controls), Gem+EMAP (m.s. 33 days, p=0.002 vs. controls)
and Gem+So+EMAP (m.s. 36 days, p=0.004 vs. controls).
Compared to the Gem monotherapy group, median sur-
vival was significantly higher in the Gem+EMAP (p=0.046)
and Gem+So+EMAP therapy group (p=0.03) but not in the
Gem+So therapy group (p=0.3). Survival in the So+EMAP
therapy group (m.s. 24 days, p=0.18 vs. control) was not
significantly different from controls or single agent therapy
groups (Figure 5). No sign of drug-related toxicity was
observed in any of the treatment groups.
Discussion
PDAC shows limited susceptibility to almost all classes
of cytotoxic drugs. Several molecular genetic abnormal-
ities in PDAC are being encountered with a high fre-
quency, including activating K-ras mutation, loss of p16,
p53 and DPC4 (deleted in pancreatic cancer, locus 4)
function, and over-expression of multiple receptor tyro-
sine kinases [36,37]. Tumor heterogeneity resulting from
the diverse molecular abnormalities acquired during ma-
lignant transformation creates a rationale to evaluate
multi-targeted therapeutic strategies against many hu-
man malignancies including PDAC. Sorafenib is a novel,
potent, small molecular mass inhibitor with combined
anticancer activities through the inhibition of tumor cell
proliferation and tumor angiogenesis. Combining conven-
tional cytotoxic drugs, such as gemcitabine, with targeted
agents that specifically interfere with key operational path-
ways responsible for PDAC progression, such as sorafenib,
is gaining more traction in the efforts to identify more ef-
fective combination treatments for PDAC.
In PDAC progression, angiogenesis plays a critical role
that is highly dependent on the complex interaction
among tumor cells, ECs, immune cells, fibroblasts and
other stromal components, all contributing to the well-
characterized extensively desmoplastic and hypoxic local
tumor microenvironment of pancreatic cancer. Specific-
ally for this reason, antiendothelial and antiangiogenic
agents may be beneficial in combination therapy ap-
proaches for PDAC treatment. In the present study we
evaluated the antitumor activity of sorafenib, and the en-
hancement of gemcitabine response by addition of
sorafenib and the antiangiogenic agent EMAP in experi-
mental pancreatic cancer. We demonstrate that in
PDAC cells sorafenib treatment effectively blocked phos-
phorylation of MEK (Ser221), ERK1/2 (Thr202/Tyr204)
and downstream target proteins phospho-p70 S6K
(Thr389) and phospho-4E-BP1 (Thr37/46) in most of
the cell lines tested except BxPC-3, where upstream
MEK and ERK phosphorylation was inhibited but not
the downstream signaling proteins p70S6K or 4-EBP-1.
These findings suggest that sorafenib may cause some
specific effects that result in blockage of Ras/Raf/MEK/
ERK signaling and interfere with pancreatic cancer cell
proliferation, differentiation and survival. Sorafenib
treatment decreased cell proliferation and induced apop-
tosis in ECs and fibroblasts indicating that the in vivo
antitumor effects of sorafenib may be due to its direct
cytotoxic effects on various tumor cellular components,
in addition to its antiangiogenic properties.
Figure 5 Effects of gemcitabine (Gem), sorafenib (So) and EMAP (E) treatment on the overall survival of mice. AsPC-1 cells (0.75 x 106)
were injected intraperitoneally in SCID mice and treatment started after 2 weeks with gemcitabine (100 mg/Kg, 2 times a week), sorafenib (30
mg/Kg, 5 times a week), and EMAP (80 μg/Kg, 5 times a week) for 2 weeks. The curve represents the survival time from the beginning of therapy.
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Previous studies have shown marked heterogeneity in
gemcitabine and other chemotherapeutic agent response
towards PADC cells [38-40]. We also observed a hetero-
geneous response of sorafenib and gemcitabine in
inhibiting cell proliferation of four PDAC lines tested.
Both agents caused inhibition of cell proliferation to
different extents and the addition of sorafenib improved
gemcitabine effects. Effects of combinations of EMAP
with sorafenib and gemcitabine were evaluated in ECs
and fibroblast cells, and a significant additive effect on
inhibition of cell proliferation was observed compared
with single or dual agent treatment. A gemcitabine plus
sorafenib combination was found to be effective in pre-
clinical and phase I trials of PDAC, lending support to
the importance of combining cytotoxic drugs with
agents inhibiting Ras/Raf/MEK/ERK pathways and
angiogenesis [9-11,13]. However, a phase II trial showed
no meaningful effect of the gemcitabine plus sorafenib
combination in advanced PDAC patients [14]. The very
small number of 17 patients and 94% of patients carry-
ing metastatic disease were the contributing factors in
the negative phase II clinical trial results [14]. These
results also indicate the importance of targeting other
relevant pathways that contribute in the progression of
PDAC. Currently, two phase II trials are evaluating the
combination treatment benefits of gemcitabine, sorafenib
and the EGFR inhibitor erlotinib in advanced PDAC.
The anti-vascular endothelial growth factor agent
bevacizumab, the first FDA-approved angiogenesis in-
hibitor, showed promising phase II data in combination
with gemcitabine in PDAC patients but failed to demon-
strate any survival benefit in phase III trials [41]. Since
sorafenib inhibits the raf kinase and VEGF pathways, we
assumed that the addition of EMAP, an inhibitor of VEGF
and integrin-fibronectin pathways [25,27], to gemcitabine
and sorafenib would potentially improve in vivo outcome
of clinical PDAC. This assumption was based on the ef-
fective in vitro combination data with EMAP in previous
studies showing EMAP enhancing antitumor effects of
gemcitabine paired with bevacizumab [21] or with the
mTOR and AKT inhibitor NVP-BEZ235 [40].
Activating K-ras mutations are highly prevalent and
have been shown to be important in the initiation and
progression of pancreatic cancer. Farnesyltransferase in-
hibitors that can block K-ras activation have been tested
clinically, but the results showed insufficient antitumor
activity perhaps indicating the importance of multi-
targeted strategies against PDAC that can extend beyond
the inhibition of a single upstream mediator within a fre-
quently activated signaling pathway [42]. Later studies
focused on therapeutic targeting of the Ras/Raf/MEK/
ERK network in combination with other important
molecular targets by multikinase inhibitors such as
sorafenib that has been shown to generate some
antitumor activity as single agent in a pancreatic cancer
cells [43]. Our results not only corroborate with these
findings, but also demonstrate the impact of sorafenib
and its combinations with gemcitabine on several other,
potentially relevant cell types and on experimental
PDAC survival. In addition, we tested combination treat-
ment benefits of sorafenib with gemcitabine and EMAP,
based on previous studies in our lab that showed
EMAP-derived improvements of gemcitabine effects
in vivo [29,31]. The observed advantages of combining
these agents can be interpreted as supportive of a ration-
ale to a multi-agent clinical approach to PDAC that in-
cludes a multikinase inhibitor, a targeted multi-pathway
blocker such as sorafenib, and an antiendothelial or
antiangiogenic agent. Although optimal combination
conditions and exact mechanisms are still not clear,
these findings may provide a solid foundation for future
evaluation of combination benefits of agents displaying
these known effects.
Based on the limited efficacy of sorafenib in a thera-
peutic approach confined to 2 weeks, prolonged or inter-
mittent dosing could be considered as an option for
achieving progression-free benefits more likely. While
we have not tested this approach in our experiments to
date, there is concern over the true ability to obtain
superior antitumor effects in the long term. Other than
the commonly known side effects that could prevent this
from being a clinically feasible strategy, persistent long
term use of sorafenib might also lead to the develop-
ment of resistant tumor cells with a more aggressive
phenotype due to some epithelial-to-mesenchymal tran-
sition (EMT) at the time of tumor recurrence [44].
Therefore an altered/decreased dose of a multikinase in-
hibitor such as sorafenib in combination with a chemo-
therapeutic and antiangiogenic/targeted agent may
provide a better therapeutic option.
In summary, our present study demonstrates that the
multikinase inhibitor sorafenib, either alone or in com-
bination with gemcitabine and EMAP, induced strong
antiproliferative and proapoptotic effects in vitro. While
the in vivo effects of sorafenib were limited, the addition
of EMAP enhanced the combination treatment of
sorafenib and gemcitabine in improving animal survival.
This provides evidence that targeting multiple mecha-
nisms of pancreatic cancer progression can be a promis-
ing therapeutic approach for PDAC treatment.
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